JP5805908B2 - Ｒｓｖに対するワクチン - Google Patents

Ｒｓｖに対するワクチン Download PDF

Info

Publication number
JP5805908B2
JP5805908B2 JP2015500925A JP2015500925A JP5805908B2 JP 5805908 B2 JP5805908 B2 JP 5805908B2 JP 2015500925 A JP2015500925 A JP 2015500925A JP 2015500925 A JP2015500925 A JP 2015500925A JP 5805908 B2 JP5805908 B2 JP 5805908B2
Authority
JP
Japan
Prior art keywords
rsv
adenovirus
protein
immunization
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015500925A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015512380A (ja
Inventor
ラドシェヴィッチ カタリナ
ラドシェヴィッチ カタリナ
エイチエイチヴイ カスターズ ジェローム
エイチエイチヴイ カスターズ ジェローム
ヴェリンガ ジョルト
ヴェリンガ ジョルト
エヌ ウィドジョジョアトモドジョ マイラ
エヌ ウィドジョジョアトモドジョ マイラ
Original Assignee
クルセル ホランド ベー ヴェー
クルセル ホランド ベー ヴェー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by クルセル ホランド ベー ヴェー, クルセル ホランド ベー ヴェー filed Critical クルセル ホランド ベー ヴェー
Publication of JP2015512380A publication Critical patent/JP2015512380A/ja
Application granted granted Critical
Publication of JP5805908B2 publication Critical patent/JP5805908B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2015500925A 2012-03-22 2013-03-21 Ｒｓｖに対するワクチン Expired - Fee Related JP5805908B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261614429P 2012-03-22 2012-03-22
EP12160682 2012-03-22
US61/614,429 2012-03-22
EP12160682.6 2012-03-22
PCT/EP2013/055935 WO2013139911A1 (en) 2012-03-22 2013-03-21 Vaccine against rsv

Publications (2)

Publication Number Publication Date
JP2015512380A JP2015512380A (ja) 2015-04-27
JP5805908B2 true JP5805908B2 (ja) 2015-11-10

Family

ID=49221877

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015500925A Expired - Fee Related JP5805908B2 (ja) 2012-03-22 2013-03-21 Ｒｓｖに対するワクチン
JP2015500926A Expired - Fee Related JP5845376B2 (ja) 2012-03-22 2013-03-21 Ｒｓｖに対するワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015500926A Expired - Fee Related JP5845376B2 (ja) 2012-03-22 2013-03-21 Ｒｓｖに対するワクチン

Country Status (15)

Country Link
EP (2) EP2827894B1 (enExample)
JP (2) JP5805908B2 (enExample)
KR (2) KR102023791B1 (enExample)
CN (2) CN104334188B (enExample)
AP (2) AP2014007994A0 (enExample)
AR (2) AR090469A1 (enExample)
AU (2) AU2013237424B2 (enExample)
BR (1) BR112014023196B1 (enExample)
CA (2) CA2867955C (enExample)
EA (2) EA026620B1 (enExample)
MY (2) MY169352A (enExample)
NZ (2) NZ630753A (enExample)
SG (2) SG11201405804YA (enExample)
TW (2) TWI624545B (enExample)
WO (2) WO2013139911A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2869841T3 (pl) 2012-07-05 2022-01-24 Glaxosmithkline Biologicals Sa Nowe schematy prime-boost wykorzystujące polipeptydy immunogenne kodowane przez polinukleotydy
BR112015025392A2 (pt) * 2013-04-08 2017-10-10 Medimmune Llc composição de vacina e método de utilização
ME03442B (me) 2013-04-25 2020-01-20 Janssen Vaccines & Prevention Bv Stabilizovani rastvorljivi pre-fuzioni rsv f polipeptidi
CN105408348B (zh) 2013-06-17 2021-07-06 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f多肽
CA2951430A1 (en) 2014-06-13 2015-12-17 Glaxosmithkline Biologicals Sa Immunogenic combinations
WO2015195961A1 (en) * 2014-06-18 2015-12-23 Georgia State University And Research Foundation, Inc. Recombinant rsv reporter virus
WO2016144675A1 (en) * 2015-03-06 2016-09-15 Medimmune, Llc Vaccine dose and use thereof
US10570417B2 (en) 2015-04-14 2020-02-25 Janssen Vaccines & Prevention B.V. Recombinant adenovirus expressing two transgenes with a bidirectional promoter
WO2016198599A1 (en) 2015-06-12 2016-12-15 Glaxosmithkline Biologicals S.A. Adenovirus polynucleotides and polypeptides
EP3319634B1 (en) 2015-07-07 2019-08-21 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion rsv f polypeptides
EP3319633B1 (en) 2015-07-07 2020-11-11 Janssen Vaccines & Prevention B.V. Vaccine against rsv
SG10202001389PA (en) 2015-12-23 2020-04-29 Pfizer Rsv f protein mutants
IL262109B2 (en) * 2016-04-05 2023-04-01 Janssen Vaccines Prevention B V vaccine against rsv
EP3439672B1 (en) 2016-04-05 2020-11-25 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion rsv f protein for use in the prophylaxis of rsv infection
ES2829272T3 (es) 2016-05-12 2021-05-31 Janssen Vaccines & Prevention Bv Promotor bidireccional potente y equilibrado
IL264119B2 (en) 2016-05-30 2023-04-01 Janssen Vaccines Prevention B V f proteins of rsv are stabilized before fusion
AU2017283118B2 (en) 2016-06-20 2019-02-07 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
WO2018146205A1 (en) 2017-02-09 2018-08-16 Janssen Vaccines & Prevention B.V. Potent and short promoter for expression of heterologous genes
WO2018210871A1 (en) * 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
CA3061278A1 (en) * 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
WO2019053109A1 (en) 2017-09-15 2019-03-21 Janssen Vaccines & Prevention B.V. METHOD FOR SAFE INDUCTION OF IMMUNITY AGAINST RSV
MX2021005607A (es) 2018-11-13 2021-06-30 Janssen Vaccines & Prevention Bv Proteinas f de prefusion del vrs estabilizadas.
EP3969044A1 (en) * 2019-05-15 2022-03-23 Janssen Vaccines & Prevention B.V. Co-administration of seasonal influenza vaccine and an adenovirus based respiratory syncytial virus vaccine
AU2020275910A1 (en) * 2019-05-15 2021-11-04 Janssen Vaccines & Prevention B.V. Prophylactic treatment of respiratory syncytial virus infection with an adenovirus based vaccine
AU2021270777A1 (en) 2020-05-12 2022-11-10 Janssen Vaccines & Prevention B.V. Administration of homologous adenoviral vectors
RU2731342C9 (ru) * 2020-08-22 2021-10-05 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Фармацевтическое средство и способ его использования для индукции специфического иммунитета против вируса тяжелого острого респираторного синдрома SARS-CoV-2 (варианты)
CN114845733A (zh) * 2020-08-22 2022-08-02 俄罗斯联邦卫生部的联邦国家预算机构“以名誉院士N.F.加马列亚命名的国家流行病学和微生物学研究中心” 抗严重急性呼吸综合征病毒SARS-CoV-2的表达载体
RU2731356C9 (ru) * 2020-08-22 2021-10-05 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Экспрессионный вектор для создания иммунобиологического средства для индукции специфического иммунитета против вируса тяжелого острого респираторного синдрома SARS-CoV-2 (варианты)
CA3152662A1 (en) * 2020-08-22 2021-04-22 Federal State Budgetary Institution "National Research Centre For Epidemiology And Microbiology Named After The Honorary Academician N.F. Gamaleya" Of The Ministry Of Health Of The Russian Federation Pharmaceutical agent for inducing specific immunity against sars-cov-2
CN112226444B (zh) * 2020-08-25 2022-11-04 北京交通大学 呼吸道合胞病毒全长融合前融合糖蛋白核苷酸序列、重组腺病毒载体及其应用产品
CN112220921B (zh) * 2020-08-25 2022-08-16 北京交通大学 一种针对呼吸道合胞病毒感染的组合疫苗
KR20230165807A (ko) * 2021-04-05 2023-12-05 가부시끼 가이샤 구보다 관리기 제어 시스템
CN117018175A (zh) * 2022-05-10 2023-11-10 康希诺生物股份公司 一种呼吸道合胞病毒腺病毒载体疫苗及其制备方法和应用
CN116003536A (zh) * 2022-09-23 2023-04-25 暨南大学 呼吸道合胞病毒融合前f蛋白突变体及其应用
WO2024093554A1 (zh) * 2022-11-04 2024-05-10 北京康乐卫士生物技术股份有限公司 针对rsv的重组亚单位疫苗及其应用
CN117050149B (zh) * 2023-05-19 2025-12-12 珠海丽凡达生物技术有限公司 包含人呼吸道合胞病毒抗原的免疫组合物及其制备方法和应用

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3584341D1 (de) 1984-08-24 1991-11-14 Upjohn Co Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
EP0784690B1 (en) 1994-06-10 2006-08-16 Genvec, Inc. Complementary adenoviral vector systems and cell lines
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5837520A (en) 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
KR100470180B1 (ko) 1995-06-15 2005-02-04 크루셀 홀란드 비.브이. 유전자 요법에 사용할 수 있는 인간의 재조합아데노바이러스 패키징 시스템
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
US5891690A (en) 1996-04-26 1999-04-06 Massie; Bernard Adenovirus E1-complementing cell lines
JP2000514290A (ja) 1996-07-01 2000-10-31 ローヌ―プーラン・ロレ・エス・アー 組換えアデノウイルスの製造方法
FR2751343B1 (fr) 1996-07-16 1998-12-18 Transgene Sa Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
JP4492826B2 (ja) 1996-11-20 2010-06-30 イントロジェン セラピューティクス，インコーポレイテッド アデノウイルスベクターの産生および精製のための改良された方法
US6261823B1 (en) 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
EP0973866A4 (en) 1997-03-04 2000-04-19 Baxter Int ADENOVIRUS E1-COMPLEMENTING CELL LINES
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US6210683B1 (en) 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
JP4358434B2 (ja) 1998-02-17 2009-11-04 シェーリング コーポレイション ウイルスを含む組成物、およびウイルス調製物を濃縮するための方法
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
EP1977764A1 (en) 1998-11-16 2008-10-08 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US6225289B1 (en) 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
PT1816205E (pt) 1999-05-17 2011-11-15 Crucell Holland Bv Adenovírus recombinante baseado no serótipo 48 (ad48)
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
DE19955558C2 (de) 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
US20020041884A1 (en) 2000-03-07 2002-04-11 Evans Robert K. Adenovirus formulations
JP4550421B2 (ja) 2001-12-12 2010-09-22 メイン・ファ−マ・インタ−ナショナル・プロプライエタリ−・リミテッド ウイルスの保存のための組成物
WO2003061708A1 (en) 2002-01-18 2003-07-31 Schering Aktiengesellschaft Stabilized formulations of adenovirus
US20030180936A1 (en) 2002-03-15 2003-09-25 Memarzadeh Bahram Eric Method for the purification, production and formulation of oncolytic adenoviruses
ATE447037T1 (de) 2002-04-25 2009-11-15 Crucell Holland Bv Mittel und verfahren zur herstellung von adenovirusvektoren
US7285265B2 (en) 2002-04-25 2007-10-23 Crucell Holland B.V. Stable adenoviral vectors and methods for propagation thereof
US7326555B2 (en) 2002-05-14 2008-02-05 Merck & Co., Inc. Methods of adenovirus purification
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
US20040106184A1 (en) 2002-08-28 2004-06-03 Introgen Therapeutics Inc. Chromatographic methods for adenovirus purification
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
CA2538025C (en) * 2003-10-02 2012-07-17 Crucell Holland B.V. Packaging cells for recombinant adenovirus
JP2007522814A (ja) 2004-02-23 2007-08-16 クルセル ホランド ベー ヴェー ウイルスの精製方法
ATE491799T1 (de) * 2004-05-26 2011-01-15 Bayer Schering Pharma Ag Chimäre adenoviren zur verwendung in der krebsbehandlung
ES2358523T3 (es) * 2004-10-13 2011-05-11 Crucell Holland B.V. Vectores adenovirales mejorados y usos de los mismos.
WO2006086284A2 (en) * 2005-02-11 2006-08-17 Merck & Co., Inc. Adenovirus serotype 26 vectors, nucleic acid and viruses produced thereby
DK1869171T4 (en) 2005-04-11 2016-01-18 Crucell Holland Bv Virus cleaning using ultrafiltration
US20100143302A1 (en) 2006-03-16 2010-06-10 Crucell Holland B.V. Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof
WO2007110409A1 (en) 2006-03-27 2007-10-04 Crucell Holland B.V. Compositions comprising a recombinant adenovirus and an adjuvant
DE102006060799A1 (de) * 2006-12-21 2008-06-26 RUHR-UNIVERSITäT BOCHUM RSV F-Protein und seine Verwendung
CN101012463A (zh) * 2007-01-19 2007-08-08 安徽医科大学 HDAd/F载体及制备方法和用途
WO2009117134A2 (en) 2008-03-21 2009-09-24 National Institutes Of Health Aerosolized genetic vaccines and methods of use
CN102203242B (zh) 2008-11-03 2013-06-12 克鲁塞尔荷兰公司 产生腺病毒载体的方法
US9095546B2 (en) 2009-07-20 2015-08-04 National Health Research Institutes Human respiratory syncytial virus (RSV) vaccine
KR101805938B1 (ko) 2009-10-15 2018-01-10 얀센 백신스 앤드 프리벤션 비.브이. 고밀도 세포 배양액에서 아데노바이러스의 정제 방법
ES2472429T3 (es) 2009-10-15 2014-07-01 Crucell Holland B.V. Método para la purificación de partículas de adenovirus a partir de cultivos de alta densidad celular
WO2011056899A2 (en) * 2009-11-03 2011-05-12 Ligocyte Pharmaceuticals, Inc. Chimeric rsv-f polypeptide and lentivirus or alpha-retrovirus gag-based vlps
EP2536829B1 (en) 2010-02-15 2016-04-06 Crucell Holland B.V. Method for the production of Ad26 adenoviral vectors
WO2012021730A2 (en) * 2010-08-11 2012-02-16 Genvec, Inc. Respiratory syncytial virus (rsv) vaccine

Also Published As

Publication number Publication date
EA201491752A1 (ru) 2015-02-27
TWI624545B (zh) 2018-05-21
AU2013237424B2 (en) 2017-07-06
KR102050616B1 (ko) 2019-12-03
CA2867950C (en) 2023-02-21
WO2013139911A1 (en) 2013-09-26
AR090470A1 (es) 2014-11-12
CA2867955A1 (en) 2013-09-26
SG11201405804YA (en) 2014-10-30
TW201341531A (zh) 2013-10-16
MY169352A (en) 2019-03-25
AP2014007994A0 (en) 2014-10-31
CN104334188A (zh) 2015-02-04
AP2014007993A0 (en) 2014-10-31
CN105431169B (zh) 2019-04-02
BR112014023196B1 (pt) 2021-09-08
KR20140138769A (ko) 2014-12-04
EP2827894A1 (en) 2015-01-28
KR102023791B1 (ko) 2019-09-23
CN105431169A (zh) 2016-03-23
AU2013237429B2 (en) 2015-07-23
MY169331A (en) 2019-03-21
BR112014023196A2 (enExample) 2017-06-20
AR090469A1 (es) 2014-11-12
SG11201405803PA (en) 2014-11-27
NZ630649A (en) 2016-12-23
TW201343669A (zh) 2013-11-01
EA026504B1 (ru) 2017-04-28
TWI640534B (zh) 2018-11-11
EP2827895B1 (en) 2017-08-09
CA2867950A1 (en) 2013-09-26
EA026620B1 (ru) 2017-04-28
CN104334188B (zh) 2016-08-24
EA201491754A1 (ru) 2014-12-30
AU2013237424A1 (en) 2014-10-16
KR20140138765A (ko) 2014-12-04
EP2827894B1 (en) 2017-05-17
JP5845376B2 (ja) 2016-01-20
AU2013237429A1 (en) 2014-10-09
WO2013139916A1 (en) 2013-09-26
NZ630753A (en) 2016-12-23
JP2015512380A (ja) 2015-04-27
EP2827895A1 (en) 2015-01-28
JP2015519295A (ja) 2015-07-09
CA2867955C (en) 2023-02-07

Similar Documents

Publication Publication Date Title
JP5805908B2 (ja) Ｒｓｖに対するワクチン
US9125870B2 (en) Vaccine against RSV
PH12014502013B1 (en) Vaccine against rsv
HK1206274B (en) Vaccine against rsv
HK1206272B (en) Vaccine against rsv
OA17889A (en) Vaccine against RSV.
OA17940A (en) Vaccine against RSV

Legal Events

Date Code Title Description
A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20150225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150310

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150708

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150818

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150902

R150 Certificate of patent or registration of utility model

Ref document number: 5805908

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees